EphA7 Antibody (G-7): sc-365647
- EphA7 Antibody (G-7) is a mouse monoclonal IgG3 provided at 200 µg/ml
- specific for an epitope mapping between amino acids 39-61 at the N-terminus of EphA7 of mouse origin
- recommended for detection of EphA7 of mouse, rat and human origin by WB, IP, IF and ELISA
- m-IgG3 BP-HRP is the preferred secondary detection reagent for EphA7 Antibody (G-7) for WB applications. This reagent is now offered in a bundle with EphA7 Antibody (G-7) (see ordering information below).
EphA7 (G-7) is a mouse monoclonal IgG3 antibody. The Eph subfamily represents the largest group of receptor protein tyrosine kinases identified to date. The Eph subfamily receptors of human origin (and their murine/avian homologs) include EphA1 (Eph), EphA2 (Eck), EphA3 (Hek4), EphA4 (Hek8), EphA5 (Hek7), EphA6 (Hek12), EphA7 (Hek11/MDK1), EphA8 (Hek3), EphB1 (Hek6), EphB2 (Hek5), EphB3 (Cek10, Hek2), EphB4 (Htk), EphB5 (Hek9) and EphB6 (Mep). EphAs are a family of receptor tyrosine kinases involved in axonal guidance during development. These receptors and their ligands, the ephrins, act via repulsive mechanisms to guide growing axons towards appropriate targets and allow for correct developmental connections. Ligand binding to an Eph receptor triggers tyrosine phosphorylation of the kinase domain, leading to repulsion of axonal growth cones and migrating cells. During neurulation, ephrin-A5 is coexpressed with EphA7 in cells at the edges of the dorsal neural folds. Three different EphA7 splice variants, a full-length form and two truncated versions lacking kinase domains, are expressed in the neural folds.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
EphA7 Antibody (G-7) References:
- Effect of EphA7 Silencing on Proliferation, Invasion and Apoptosis in Human Laryngeal Cancer Cell Lines Hep-2 and AMC-HN-8. | Xiang, C., et al. 2015. Cell Physiol Biochem. 36: 435-45. PMID: 25968442
- Ligand-dependent EphA7 signaling inhibits prostate tumor growth and progression. | Li, S., et al. 2017. Cell Death Dis. 8: e3122. PMID: 29022918
- Identification of the soluble EphA7-interacting protein Nicalin as a regulator of EphA7 expression. | Wang, X. and Wang, Z. 2021. Mol Cell Biochem. 476: 213-220. PMID: 32914261
- EphA7 isoforms differentially regulate cortical dendrite development. | Leonard, CE., et al. 2020. PLoS One. 15: e0231561. PMID: 33275600
- EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers. | Zhang, Z., et al. 2021. BMC Med. 19: 26. PMID: 33526018
- Satb2 Regulates EphA7 to Control Soma Spacing and Self-Avoidance of Cortical Pyramidal Neurons. | He, CH., et al. 2022. Cereb Cortex. 32: 2321-2331. PMID: 34546353
- Loss of EphA7 Expression in Basal Cell Carcinoma by Hypermethylation of CpG Islands in the Promoter Region. | Liu, J., et al. 2022. Anal Cell Pathol (Amst). 2022: 4220786. PMID: 35103233
- The identification and validation of EphA7 hypermethylation, a novel biomarker, in cervical cancer. | Zhang, W., et al. 2022. BMC Cancer. 22: 636. PMID: 35681118
- Modulation of EphA7 and pEphA7 Protein Expression: Potential Biomarkers for Early Detection of Hepatocellular Carcinoma. | Priya, S. and Kma, L. 2022. Asian Pac J Cancer Prev. 23: 2843-2850. PMID: 36037142
- STAT3-EphA7 axis contributes to the progression of esophageal squamous cell carcinoma. | Wang, L., et al. 2023. Acta Oncol. 62: 1757-1766. PMID: 37738252
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
EphA7 Antibody (G-7) | sc-365647 | 200 µg/ml | $322.00 | |||
EphA7 Antibody (G-7): m-IgG3 BP-HRP Bundle | sc-550433 | 200 µg Ab; 40 µg BP | $361.00 | |||
EphA7 (G-7) Neutralizing Peptide | sc-365647 P | 100 µg/0.5 ml | $69.00 |